395 related articles for article (PubMed ID: 2857672)
1. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
[TBL] [Abstract][Full Text] [Related]
2. Famotidine: effective treatment of Zollinger-Ellison syndrome.
Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
[TBL] [Abstract][Full Text] [Related]
3. Famotidine in the therapy of gastric hypersecretory states.
Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
[TBL] [Abstract][Full Text] [Related]
4. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
[TBL] [Abstract][Full Text] [Related]
5. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
Campoli-Richards DM; Clissold SP
Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
[TBL] [Abstract][Full Text] [Related]
6. Comparison of famotidine with cimetidine and ranitidine.
Berardi RR; Tankanow RM; Nostrant TT
Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Maton PN; Gardner JD; Jensen RT
Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
[TBL] [Abstract][Full Text] [Related]
8. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
[TBL] [Abstract][Full Text] [Related]
9. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
Maton PN
Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
[TBL] [Abstract][Full Text] [Related]
10. Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome.
Saeed ZA; Norton JA; Frank WO; Young MD; Maton PN; Gardner JD; Jensen RT
Gastroenterology; 1989 Jun; 96(6):1393-402. PubMed ID: 2565842
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion.
Collen MJ; Howard JM; McArthur KE; Raufman JP; Cornelius MJ; Ciarleglio CA; Gardner JD; Jensen RT
Ann Intern Med; 1984 Jan; 100(1):52-8. PubMed ID: 6318628
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.
Jensen RT; Collen MJ; McArthur KE; Howard JM; Maton PN; Cherner JA; Gardner JD
Am J Med; 1984 Nov; 77(5B):90-105. PubMed ID: 6150641
[TBL] [Abstract][Full Text] [Related]
13. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
Dammann HG; Müller P; Simon B; Kommerell B
Z Gastroenterol; 1984 Jun; 22(6):318-20. PubMed ID: 6147052
[No Abstract] [Full Text] [Related]
14. Ranitidine and cimetidine in Zollinger-Ellison syndrome.
Mignon M; Vallot T; Mayeur S; Bonfils S
Br J Clin Pharmacol; 1980 Aug; 10(2):173-4. PubMed ID: 6107118
[No Abstract] [Full Text] [Related]
15. Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
Saha N; Sachdev A; Bhasin DK; Sankaranahyanan A; Khosla PP; Singh K; Sharma PL
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):322-5. PubMed ID: 8103763
[TBL] [Abstract][Full Text] [Related]
16. [The role of H2 antagonists in Zollinger-Ellison syndrome].
Dammann HG; Walter TA; Müller P; Simon B
Clin Ter; 1984 Dec; 111(5):393-400. PubMed ID: 6151434
[No Abstract] [Full Text] [Related]
17. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
Langtry HD; Grant SM; Goa KL
Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
[TBL] [Abstract][Full Text] [Related]
18. [Strong inhibition of gastric acid secretion: when is it justifiable?].
Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
[No Abstract] [Full Text] [Related]
19. Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
Helman CA; Tim LO
Pharmacotherapy; 1983; 3(4):185-92. PubMed ID: 6136952
[TBL] [Abstract][Full Text] [Related]
20. What are the differences between the H2-receptor antagonists?
Schunack W
Aliment Pharmacol Ther; 1987; 1 Suppl 1():493S-503S. PubMed ID: 2908767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
